Celator Pharmaceuticals Company Profile (NASDAQ:CPXX)

Analyst Ratings

Consensus Ratings for Celator Pharmaceuticals (NASDAQ:CPXX) (?)
Ratings Breakdown: 4 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $18.67 (38.27% downside)

Analysts' Ratings History for Celator Pharmaceuticals (NASDAQ:CPXX)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Roth CapitalDowngradeBuy -> Neutral$30.25 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016HC WainwrightBoost Price TargetBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015FBR & CoReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Celator Pharmaceuticals (NASDAQ:CPXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q116($0.15)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2016Q4($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.16)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.14)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015($0.16)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.21)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.20)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014($0.24)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2014Q4 13($0.15)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013($0.20)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celator Pharmaceuticals (NASDAQ:CPXX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20162($0.15)($0.14)($0.15)
Q3 20162($0.16)($0.14)($0.15)
Q4 20162($0.18)($0.13)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celator Pharmaceuticals (NASDAQ:CPXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/3/2015Scott D MorensteinDirectorBuy5,000$1.87$9,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Scott Thomas JacksonCEOBuy14,450$1.74$25,143.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Fred M PowellCFOBuy13,700$1.78$24,386.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Life Sciences Gp Ll Valence IIinsiderBuy12,200$1.64$20,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Fred M PowellCFOBuy6,000$2.20$13,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Michael R DoughertyDirectorBuy20,000$2.15$43,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Scott Thomas JacksonCEOBuy10,000$2.20$22,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Fred M PowellCFOBuy2,500$2.50$6,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Fred M PowellCFOBuy2,500$3.50$8,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Scott Thomas JacksonCEOBuy3,000$3.50$10,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celator Pharmaceuticals (NASDAQ:CPXX)
DateHeadline
07/29/16 03:28 PMNew Broker Ratings For Celator Pharmaceuticals Inc. (CPXX) - FTSE News
07/27/16 11:29 AMMoleculin Biotech Inc (NASDAQ:MBRX): Proceed With Caution
07/27/16 11:29 AMActinium: Another Promising Name in the AML Space
07/20/16 10:43 PMAre Analysts Bearish Celator Pharmaceuticals Inc (NASDAQ:CPXX) After Last Week? - Consumer Eagle
07/20/16 04:30 PMCelator Pharmaceuticals Inc. (NASDAQ:CPXX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/19/16 08:43 PMSolid Performer in Focus: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - Engelwood Daily
07/16/16 05:31 AMInstitutional Investors Positive on Celator Pharmaceuticals Inc (NASDAQ:CPXX) - Press Telegraph
07/15/16 09:19 AMInvestor News: Lawsuit against Buyout of Celator Pharmaceuticals Inc (NASDAQ:CPXX) filed - GroundReport
07/13/16 03:29 PMInvestor News: Lawsuit against Buyout of Celator Pharmaceuticals Inc (NASDAQ:CPXX) filed
07/13/16 02:51 PMA Look at Jazz Pharmaceuticals’ Celator Acquisition Deal -
07/13/16 02:51 PMWhy Did Jazz Fall after Celator Acquisition Announcement? -
07/13/16 10:46 AMCelator Pharmaceuticals Inc. (NASDAQ:CPXX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 10:46 AMBroker Outlook For Celator Pharmaceuticals Inc. (CPXX) - Fiscal Standard
07/12/16 03:29 PMCelator Pharmaceuticals Inc Upside Stock Momentum at Extreme Strength - CML News
07/12/16 03:29 PMAnalyst Target and Average Rating Watch: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) - Press Telegraph
07/12/16 03:02 PMCELATOR PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi -
07/12/16 07:40 AMAnalysts Reviewing Stocks: InspireMD, Inc. (NYSEMKT:NSPR) , Celator Pharmaceuticals Inc. (NASDAQ:CPXX) - Street Updates
07/12/16 07:40 AMJazz Pharmaceuticals (JAZZ) Offers Results from Celator Pharma (CPXX) Tender Offer - StreetInsider.com
07/12/16 01:03 AMJazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc. - [at noodls] - DUBLIN, July 12, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals, ...
07/11/16 08:10 AMStock on the Rise for the Quarter: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - Engelwood Daily
07/10/16 03:12 PMNext Weeks Broker Price Targets For Celator Pharmaceuticals Inc. (CPXX) - Fiscal Standard
07/07/16 12:33 PMSteven Cohen Hits Another Home Run in Oncology -
07/06/16 09:10 PMCan Celator Pharmaceuticals Inc. (NASDAQ:CPXX) Improve on the Earnings Front? - Engelwood Daily
07/05/16 03:21 PMCelator Pharmaceuticals Incorporated (NASDAQ:CPXX) Shorted Shares Decreased By 38.24% - Press Telegraph
07/05/16 11:01 AMHercules Provides Portfolio Update for Q2 2016 and Highlights Con ... - [at noodls] - Closed New Debt and Equity Commitments to Date for Q2 2016 of $203.9 million Eight (8) new commitments to venture growth stage innovative technology, life sciences and sustainable & renewable technology ...
07/01/16 03:23 PMShort Term Price Target on Celator Pharmaceuticals (CPXX) - Trade Calls
06/30/16 03:39 PMRecently Issued Stock Ratings For Celator Pharmaceuticals Inc. (CPXX) - Fiscal Standard
06/30/16 10:14 AMCelator Pharmaceuticals Incorporated (NASDAQ:CPXX) Short Interest Decreased By 38.24% - Press Telegraph
06/28/16 03:21 PMCovering the Bases on Celator Pharmaceuticals Inc. (NASDAQ:CPXX): Where is the Stock Going? - Press Telegraph
06/28/16 03:21 PMHow Many Celator Pharmaceuticals Inc (NASDAQ:CPXX)'s Analysts Are Bullish? - Press Telegraph
06/27/16 07:21 AMWhy Celator Pharmaceuticals Is Up 1,610% in 2016 -
06/26/16 11:09 PMJazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition - [PR Newswire] - As previously announced on May 31, 2016, Jazz Pharmaceuticals and Celator entered into a definitive merger agreement under which Jazz Pharmaceuticals has commenced a tender offer for all of the outstanding shares of Celator at $30.25 per share in cash, representing total consideration of approximately $1.5 billion. The expiration of the HSR waiting period satisfies one of the conditions required to consummate the tender offer. The closing of the tender offer remains subject to other customary conditions, including the tender of a majority of the outstanding shares of Celator common stock. The tender offer and withdrawal rights will expire at one minute following 11:59 p.m., New York City Time, on July 11, 2016, unless the tender offer is extended or terminated earlier in accordance with the terms of the definitive merger agreement. The Offer to Purchase dated June 10, 2016, relating to the tender offer has been filed with the United States Securities and Exchange Commission ("SEC") and can be viewed online, along with any amendments thereto, at www.sec.gov.
06/24/16 03:31 PMShares Reaching Overbought Territory: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - Press Telegraph
06/24/16 03:31 PMPrice Target Update on Celator Pharmaceuticals (NASDAQ:CPXX) - Trade Calls
06/23/16 02:48 PMCelator Pharmaceuticals Inc. (CPXX) Current Analyst Ratings - Fiscal Standard
06/23/16 02:48 PMCelator Pharmaceuticals Inc. (CPXX) Updated Price Targets - FTSE News
06/22/16 08:30 AMSlingshot Insights Hosts Informative Call On Moleculin Biotech: Here Are The Details - Slingshot Insights, a crowdfunded expert network that offers investment research tools, conducted an expert call on Moleculin Biotech Inc (NASDAQ: MBRX) AML drug Annamycin last Friday. The goal of the call was to offer investors the opportunity to better understand how the drug differs from competing drugs, such as Celator Pharmaceuticals Inc (NASDAQ: CPXX)'s VYXEOS. Slingshot Insights' expert on the call was medical oncologist and professor at Johns Hopkins University Dr. Gabriel Ghiaur. The doctor is also a double board certified in Hematology and Internet Medicine, with numerous publications ...Full story available on Benzinga.com
06/20/16 03:20 PMCelator Pharmaceuticals Inc. (CPXX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 03:14 PMMost Recent Update on Price Moves: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , Acadia Healthcare Company ... - Street Updates
06/15/16 08:07 AMStock's Price Moves: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) , Celator Pharmaceuticals Inc. (NASDAQ:CPXX) - Street Updates
06/15/16 08:07 AMCutting Edge Stocks in Focus- Celator Pharmaceuticals (NASDAQ:CPXX), Telefonaktiebolaget LM Ericsson (NASDAQ ... - Seneca Globe
06/14/16 09:09 PMYale Joins PTX’s Phase 1b/2 AML Clinical Trial - [at noodls] - 5535e098-6096-474f-b2ed-3925471117d7.pdf ASX Release Yale Joins PTX's Phase 1b/2 AML Clinical Trial Melbourne, Australia - (15 June, 2016) - Clinical-stage oncology company Prescient Therapeutics Limited ...
06/14/16 03:16 PMHC Stocks Reports: Celator Pharmaceuticals Inc (NASDAQ:CPXX), Geron Corporation (NASDAQ:GERN) - share market updates (press release)
06/14/16 03:16 PMStocks Earnings Analysis Report: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), Digital Realty Trust Inc. (NYSE:DLR) - Beacon Chronicle
06/14/16 07:41 AMCompany Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces Positive Results in Patients with FLT3 ... - Smarter Analyst
06/13/16 02:49 PMAnalyst Overview on these Stocks: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), Uranium Energy Corp. (NYSEMKT ... - Beacon Chronicle
06/11/16 03:28 PMAnalysts Rating Alert: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , Jaguar Animal Health, Inc. (NASDAQ:JAGX) - Street Updates
06/08/16 05:36 PMSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX - [Accesswire] - BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" ...
06/07/16 03:28 PMStock under Analyst' Radar: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - News Oracle
06/07/16 11:42 AMStocks within Traders Radar: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , CytRx Corporation (NASDAQ:CYTR) - Street Updates

Social

About Celator Pharmaceuticals

Celator Pharmaceuticals logoCelator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPXX
  • CUSIP:
Key Metrics:
  • Previous Close: $30.24
  • 50 Day Moving Average: $28.68
  • 200 Day Moving Average: $12.63
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 7.09
  • Current Year EPS Consensus Estimate: $-0.60 EPS
  • Next Year EPS Consensus Estimate: $-0.33 EPS
Additional Links:
Celator Pharmaceuticals (NASDAQ:CPXX) Chart for Friday, July, 29, 2016